Data presented at the American Society of Clinical Oncology meeting in 2011 showed that 6 months of treatment with capecitabine, an oral chemotherapy agent, costs US$ 3 to 8 thousand in countries such as Argentina and Egypt, while that of an aromatase inhibitor, also used to treat metastatic disease, may cost a lot less (US$ 500.00 to US$ 1,400.00) (23). The gene discussed is CYP19A1; the disease is metastatic neoplasm.